Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Issued Date
2024-01-01
Resource Type
ISSN
15455009
eISSN
15455017
Scopus ID
2-s2.0-85193250086
Journal Title
Pediatric Blood and Cancer
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Blood and Cancer (2024)
Suggested Citation
Forni G.L., Kattamis A., Kuo K.H.M., Maggio A., Sheth S., Taher A.T., Viprakasit V. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?. Pediatric Blood and Cancer (2024). doi:10.1002/pbc.31035 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98466
Title
Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Corresponding Author(s)
Other Contributor(s)
Abstract
In this review, we provide a summary of evidence on iron overload in young children with transfusion-dependent β-thalassemia (TDT) and explore the ideal timing for intervention. Key data from clinical trials and observational studies of the three available iron chelators deferoxamine, deferiprone, and deferasirox are also evaluated for inclusion of subsets of young children, especially those less than 6 years of age. Evidence on the efficacy and safety of iron chelation therapy for children ≥2 years of age with transfusional iron overload is widely available. New data exploring the risks and benefits of early-start iron chelation in younger patients with minimal iron overload are also emerging.